Bortezomib

PL Zinzani

doi:10.4081/hmr.v2i13.496

Articles

10 June 2009

Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006

https://doi.org/10.4081/hmr.v2i13.496

Bortezomib

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

177

Views

201

Downloads

Authors

PL Zinzani

support@pagepress.org

The incidence of non-Hodgkin's lymphoma (NHL) has markedly increased in the US and Western Europe in recent years and presents a considerable clinical challenge. Despite many advances in the treatment of NHL, the challenge to develop treatments for the disease remains. For example, there are few effective treatment options for patients with mantle cell lymphoma (MCL) and, while there are a number of therapies that can induce remission in patients with follicular lymphoma (FL), the disease remains incurable. Recently, preclinical and clinical studies have shown the potential for proteasome inhibition in the treatment of NHL.